PL3448416T3 - Semaglutyd w schorzeniach sercowo-naczyniowych - Google Patents

Semaglutyd w schorzeniach sercowo-naczyniowych

Info

Publication number
PL3448416T3
PL3448416T3 PL17721109.1T PL17721109T PL3448416T3 PL 3448416 T3 PL3448416 T3 PL 3448416T3 PL 17721109 T PL17721109 T PL 17721109T PL 3448416 T3 PL3448416 T3 PL 3448416T3
Authority
PL
Poland
Prior art keywords
semaglutide
cardiovascular conditions
cardiovascular
conditions
Prior art date
Application number
PL17721109.1T
Other languages
English (en)
Inventor
Oluf Kristian Højbjerg HANSEN
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3448416(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL3448416T3 publication Critical patent/PL3448416T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
PL17721109.1T 2016-04-28 2017-04-28 Semaglutyd w schorzeniach sercowo-naczyniowych PL3448416T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
PL3448416T3 true PL3448416T3 (pl) 2022-11-07

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17721109.1T PL3448416T3 (pl) 2016-04-28 2017-04-28 Semaglutyd w schorzeniach sercowo-naczyniowych

Country Status (24)

Country Link
US (3) US12569543B2 (pl)
EP (1) EP3448416B1 (pl)
JP (1) JP7221694B2 (pl)
KR (3) KR102778218B1 (pl)
CN (1) CN109069589B (pl)
AU (2) AU2017256774B2 (pl)
BR (1) BR112018072020A2 (pl)
CA (1) CA3022535A1 (pl)
CL (1) CL2018003045A1 (pl)
DK (1) DK3448416T3 (pl)
ES (1) ES2928007T3 (pl)
HR (1) HRP20221150T1 (pl)
HU (1) HUE060040T2 (pl)
IL (1) IL262390B1 (pl)
MA (1) MA44762A (pl)
MX (1) MX2018012700A (pl)
MY (1) MY202967A (pl)
PH (1) PH12018502274B1 (pl)
PL (1) PL3448416T3 (pl)
RS (1) RS63630B1 (pl)
RU (1) RU2768283C2 (pl)
SI (1) SI3448416T1 (pl)
WO (1) WO2017186896A1 (pl)
ZA (2) ZA202507394B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12569543B2 (en) * 2016-04-28 2026-03-10 Novo Nordisk A/S Semaglutide in cardiovascular conditions
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
IL281938B2 (en) * 2018-10-26 2024-04-01 Novo Nordisk As Stable semaglutide compositions and uses thereof
JP7410952B2 (ja) * 2018-12-21 2024-01-10 ノヴォ ノルディスク アー／エス Ｇｌｐ－１ペプチドの噴霧乾燥のプロセス
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
EP4536691A1 (en) * 2022-06-08 2025-04-16 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119734A1 (en) * 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
JP2005535569A (ja) 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA030999B1 (ru) 2009-10-02 2018-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Применение фармацевтической композиции, включающей ингибитор дпп-4 и гидрохлорид метформина
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
US20150290294A1 (en) 2012-11-02 2015-10-15 Mansoor Husain Methods for inhibiting platelet aggregation using glp-1 receptor agonists
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
KR20210099201A (ko) 2013-03-15 2021-08-11 베링거 인겔하임 인터내셔날 게엠베하 심장보호 및 신장보호 항당뇨병 치료요법에서의 리나글립틴의 사용
US10246497B2 (en) * 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
US12569543B2 (en) * 2016-04-28 2026-03-10 Novo Nordisk A/S Semaglutide in cardiovascular conditions

Also Published As

Publication number Publication date
KR20250038818A (ko) 2025-03-19
MX2018012700A (es) 2019-01-30
KR20180135012A (ko) 2018-12-19
US20250288649A1 (en) 2025-09-18
ZA202507395B (en) 2025-09-25
BR112018072020A2 (pt) 2019-02-12
EP3448416B1 (en) 2022-08-10
ZA202507394B (en) 2025-09-25
HUE060040T2 (hu) 2023-01-28
AU2024227113A1 (en) 2024-10-31
IL262390B1 (en) 2023-05-01
CA3022535A1 (en) 2017-11-02
KR102778218B1 (ko) 2025-03-10
RU2018140900A3 (pl) 2020-09-28
KR20220147712A (ko) 2022-11-03
PH12018502274A1 (en) 2019-09-09
US20250262281A1 (en) 2025-08-21
RU2768283C2 (ru) 2022-03-23
US20190134162A1 (en) 2019-05-09
MA44762A (fr) 2019-03-06
US12569543B2 (en) 2026-03-10
CL2018003045A1 (es) 2018-12-14
JP7221694B2 (ja) 2023-02-14
AU2017256774B2 (en) 2024-07-11
MY202967A (en) 2024-05-31
IL262390A (en) 2018-12-31
DK3448416T3 (da) 2022-10-03
AU2017256774A1 (en) 2018-11-01
RU2018140900A (ru) 2020-05-28
PH12018502274B1 (en) 2024-02-28
HRP20221150T1 (hr) 2022-11-25
SI3448416T1 (sl) 2022-10-28
CN109069589A (zh) 2018-12-21
ES2928007T3 (es) 2022-11-14
CN109069589B (zh) 2022-09-06
WO2017186896A1 (en) 2017-11-02
RS63630B1 (sr) 2022-10-31
EP3448416A1 (en) 2019-03-06
JP2019514925A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
GB2546350B (en) Compositions and methods
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL262390A (en) Semaglutide in cardiovascular conditions
TWI560818B (en) Electronic package and the manufacture thereof
IL256020B (en) Igfbp3 and uses thereof
ZA201801052B (en) Combinations and uses thereof
GB201512044D0 (en) Application in German
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
GB201521190D0 (en) Application in german
ZA201805538B (en) Liraglutide in cardiovascular conditions
TWI561958B (en) Integrated circuit
IL254241A0 (en) Etv2 and its uses
GB201603976D0 (en) Application in foreign
GB201512996D0 (en) Compositions and methods
GB201407256D0 (en) Sercure token implementation
GB201523035D0 (en) In terferometry
GB201603974D0 (en) Application in foreign
GB201505011D0 (en) Improvements in packages
GB201521191D0 (en) Application in german
PT3448416T (pt) Semaglutido em condições cardiovasculares
GB201508643D0 (en) Improvements in shirts
GB201508028D0 (en) Sandfalls and the like
PT3423082T (pt) Liraglutida em condições cardiovasculares
GB201618109D0 (en) Improvements in drawing boards